Table 1 Demographic and disease characteristics of the study population
|  | All patients (number = 291) | RA on MTX (number = 50) | RA on anti-TNF monotherapy (number = 38) | RA on anti-TNF + MTX (number = 53) | RA on abatacept (number = 5) | RA on rituximab (number = 10) | RA on tocilizumab (number = 2) | SpA on anti-TNF monotherapy (number = 41) | SpA on anti-TNF + MTX (number = 51) | SpA on NSAIDs/ analgesics controls (number = 41) |
|---|---|---|---|---|---|---|---|---|---|---|
Age (years) mean (range) | 57 (23 to 87) | 62.3 (26 to 87) | 62.4 (32 to 86) | 61.1 (41 to 83) | 55.2 (43 to 66) | 62.3 (43 to 79) | 63.5 (55 to 72) | 49.0 (2 to 69) | 52.6 (26 to 71) | 52.2 (23 to 72) |
Gender (% female) | 64 | 78 | 84 | 80 | 86 | 80 | 100 | 37 | 51 | 51 |
Disease duration (years) mean (range) | 16.0 (1 to 55) | 12.5 (1 to 41) | 21.1 (3 to 46) | 18.2 (2 to 48) | 12.4 (6 to 24) | 22.3 (5 to 55) | 21.5 (15 to 28) | 16.6 (1 to 36) | 13.1 (1 to 42) | 14.3 (1 to 37) |
RF positive (%) | 43 | 76 | 87 | 76 | 100 | 80 | 100 | ----- | ----- | ---- |
Anti-CCP positive (%) | 43 | 82 | 74 | 83 | 80 | 80 | 50 | ------ | ----- | …… |
HLA-B27 positve (%) | 22.3 | ----- | ------ | ----- | ------ | ------- | ------ | 56 | 28 | 68 |